Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Oxaliplatin in Treatment of the Cisplatin-resistant MKN45 Cell Line of Gastric Cancer

KATSUYUKI TOZAWA, TADAYUKI OSHIMA, TAKEHIKO KOBAYASHI, NORIYASU YAMAMOTO, CHIZUKO HAYASHI, TAKAYUKI MATSUMOTO and HIROTO MIWA
Anticancer Research July 2008, 28 (4B) 2087-2092;
KATSUYUKI TOZAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TADAYUKI OSHIMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKEHIKO KOBAYASHI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORIYASU YAMAMOTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHIZUKO HAYASHI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAYUKI MATSUMOTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROTO MIWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: miwahgi@hyo-med.ac.jp
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background and Aim: The clinical efficiency of cisplatin (CDDP) against gastric cancer is often limited by the development of resistance. A third-generation platinum-containing agent, oxaliplatin (L-OHP), has been introduced for treating gastric cancer. Here, we studied oxaliplatin in vitro to reveal the mechanism of acquiring drug resistance and whether a cisplatin-resistant gastric cancer cell line has susceptibility to oxaliplatin. Materials and Methods: A cisplatin-resistant gastric cancer cell line (MKN45/CDDP/R1) was established by continuous exposure of MKN45 cells to cisplatin. The amount of excision repair cross-complementation group 1 (ERCC1) and glutathione-S-transferase (GST)-π mRNA was measured by real-time polymerase chain reaction (PCR). To examine the chemosensitivity to CDDP and L-OHP in MKN45 and MKN45/CDDP/R1 cells, a collagen gel droplet-embedded culture drug sensitivity test (CD-DST) was performed. The intracellular concentration of CDDP and L-OHP were also measured to see if the drugs would be taken up by these cell lines. Results: The MKN45/CDDP/R1 cell line was resistant to CDDP. The ERCC1 and GST-π mRNA was significantly increased in MKN45/CDDP/R1 cells, indicating that the cells acquired resistance to CDDP. Intracellular CDDP was not detected in MKN45/CDDP/R1 cells up to 48 h after incubation, indicating that uptake and efflux processes of CDDP were altered in these cells. MKN45/CDDP/R1 cells were still susceptible to L-OHP. The intracellular concentration of CDDP but not L-OHP was significantly reduced in MKN45/CDDP/R1 cells. Conclusion: We established a CDDP-resistant cell line using MKN45 cells, in which ERCC1 and GST-π were increased. This cell line showed susceptibility to the new generation platinum agent L-OHP, suggesting this anticancer agent could be used in second-line treatment of patients with CDDP-resistant gastric neoplasms.

  • Gastric cancer
  • CDDP-resistant cell line
  • oxaliplatin
  • ERCC1
  • GST-π
  • MKN45

Footnotes

  • Received February 13, 2008.
  • Revision received April 8, 2008.
  • Accepted May 2, 2008.
  • Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (4B)
Anticancer Research
Vol. 28, Issue 4B
July-August 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Oxaliplatin in Treatment of the Cisplatin-resistant MKN45 Cell Line of Gastric Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Oxaliplatin in Treatment of the Cisplatin-resistant MKN45 Cell Line of Gastric Cancer
KATSUYUKI TOZAWA, TADAYUKI OSHIMA, TAKEHIKO KOBAYASHI, NORIYASU YAMAMOTO, CHIZUKO HAYASHI, TAKAYUKI MATSUMOTO, HIROTO MIWA
Anticancer Research Jul 2008, 28 (4B) 2087-2092;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Oxaliplatin in Treatment of the Cisplatin-resistant MKN45 Cell Line of Gastric Cancer
KATSUYUKI TOZAWA, TADAYUKI OSHIMA, TAKEHIKO KOBAYASHI, NORIYASU YAMAMOTO, CHIZUKO HAYASHI, TAKAYUKI MATSUMOTO, HIROTO MIWA
Anticancer Research Jul 2008, 28 (4B) 2087-2092;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance
  • Multi-center Randomized Phase II Study of Weekly Docetaxel Versus Weekly Docetaxel-plus-Oxaliplatin as a Second-line Chemotherapy for Patients with Advanced Gastric Cancer
  • Google Scholar

More in this TOC Section

  • C-myc Oncogene Numerical Imbalances Analysis in Laryngeal Squamous Cell Carcinoma
  • Association of Interleukin-12A Genotypes With Nasopharyngeal Carcinoma Risk
  • Immunogenicity of Neoantigens in Colorectal Cancer: Potential Influence of Tumor Mutation Burden, Stages, and Metastasis
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire